Eli Lilly acquires SiteOne Therapeutics for up to $1B, signaling potential uptick in Big Pharma deals and focus on non-opioid ...

Eli Lilly and Company (NYSE:LLY) is expanding its footprint into the non-opioid pain management market in pursuit of growth ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

If approved by regulators, the acquisition would give Lilly strategic access to STC-004, an experimental non-opioid pain medication that is part of a class of drugs called Nav1.8 inhibitors.

SiteOne Therapeutics is developing a non-opioid therapy that targets sodium ion channels in the human body to treat pain and ...

Eli Lilly has agreed to acquire the pain-treatment company SiteOne Therapeutics for up to $1 billion in cash. The drug company said Tuesday that the acquisition includes SiteOne's STC-004, which is ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

If you are looking to get a weight loss drug but lack insurance coverage, telehealth websites such as Ro, Hers and Mochi Health sell GLP-1 drugs for lower prices than what you’d pay at a pharmacy, ...

Compounding pharmacies, that produced the weight loss drugs at a fraction of their brand name price, are being forced to stop ...

The Woodlands Township Board of Directors has agreed to begin exploring what it would take to recruit a luxury hotel brand ...

St. Xavier, Manual, Trinity, Assumption, Spencer County and Shelby County won team titles at Wednesday's Louisville-area track and field regionals.

The findings were released Thursday by the American Society of Clinical Oncology and will be discussed at its annual meeting.